NO

NEXT Oncology at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

NEXT Oncology takes part in 3 sessions at ESMO 2026 in Madrid. Its program centres on developmental therapeutics, the early clinical testing of new cancer drugs. It presents overall survival results from the first-in-human study of telisotuzumab adizutecan in nonsquamous non-small cell lung cancer.

OrganizationESMO 2026 Attendance
NO
NEXT Oncology
Pozuelo de Alarcon, Spain
Cancer centre & hospital
Early-phase cancer drug trial unit of a US-based clinical research network, located in a Quirónsalud private hospital in Pozuelo de Alarcón, Spain.
Abstract
Sat Oct 24
09:27–09:32
Chair
Sat Oct 24
14:45–16:15
Proffered paper: Developmental therapeutics
with MD Anderson Cancer Center
Talk
Tue Oct 27
11:20–11:40
Developmental therapeutics
Scientific Congress Highlights 1

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from NEXT Oncology

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction